Ligand's Partner Travere Therapeutics Announces Confirmatory Data From The Phase 3 Protect Study Of Filspari Demonstrating Long-Term Kidney Function Preservation In IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint Versus Active Control
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics, a partner of Ligand Pharmaceuticals, announced confirmatory data from the Phase 3 Protect Study of Filspari, demonstrating long-term kidney function preservation in IgA Nephropathy. However, the study narrowly missed the eGFR total slope endpoint versus active control.
September 21, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ligand Pharmaceuticals' partner, Travere Therapeutics, announced confirmatory data from a Phase 3 study of Filspari. The study narrowly missed the eGFR total slope endpoint, which may impact investor sentiment towards Ligand.
As a partner of Travere Therapeutics, Ligand Pharmaceuticals has a vested interest in the success of Filspari. The fact that the Phase 3 study narrowly missed a key endpoint could negatively impact investor sentiment towards Ligand, potentially leading to a short-term decrease in its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75